Black Diamond reports positive Phase 2 data for silevertinib in NSCLC patients

Black Diamond Therapeutics announced positive Phase 2 results for silevertinib showing 15.2 months median PFS and 86% CNS ORR in frontline NSCLC patients with EGFR non-classical mutations. The data supports potential regulatory approval and positions the therapy as a practice-changing treatment for an underserved patient population.